Document is current

Article History

Received: 14 January 2019

Accepted: 16 December 2019

First Online: 15 January 2020

Competing interests

: MG was a recipient of the BMRI/McGill University Multiple Sclerosis scholarship, funded by Novartis and has received travel grants and/or speaker fees from Novartis, Sanofi-Genzyme, Roche, Teva and Biogen Idec. AR, RL and AE report no disclosures. PSG has received personal compensation for speaking, consulting, and advisory board participation from Allergan, Bayer HealthCare, Biogen Idec, EMD Serono, Genzyme, Novartis, Roche and Teva Neuroscience, has received research support from Biogen Idec and Teva Neuroscience, has been a consultant for NeuroRx Research, an imaging Contract Research Organization, and has acted as a principal investigator or sub-investigator for clinical trials for Alexion, Bayer HealthCare, Biogen Idec, Elan, EMD Serono, GlaxoSmithKline, Novartis, Ono, Roche-Genentech, Sanofi-Aventis and Teva Neuroscience. MHB has received institutional support for research, speaking and/or participation in advisory boards from Biogen, Merck, Novartis, Roche and Sanofi Genzyme, is a consulting neurologist for RxMx/Medical Safety Systems and the research director for the Sydney Neuroimaging Analysis Centre. JA serves on advisory/safety monitoring boards for Novartis, Sanofi-Genzyme, Biogen Idec, EMD Serono and Medday Pharmaceuticals, and as editor of the Americas, Multiple Sclerosis Journal. ABO has participated as a speaker at meetings sponsored by, received consulting fees and/or received grant support from: Amplimmune, Bayhill Therapeutics, Berlex/Bayer, Biogen Idec, Diogenix, Eli-Lilly, Genentech, GlaxoSmithKline, Guthy-Jackson/GGF, Merck/EMD Serono, Medimmune, Mitsubishi Pharma, Novartis, Ono Pharma, Receptos, Roche, Sanofi-Genzyme, Teva Neuroscience, Wyeth.